Johnson & Johnson

- Johnson & Johnson completed the Kenvue separation, which included debt offering and IPO, generating significant cash and value for shareholders. - Post-separation, Johnson & Johnson reduced its outstanding share count by approximately 7% (191 million shares). - The company retained around 180 million shares of Kenvue stock, providing cash proceeds for future use. - Johnson & Johnson ended Q3 2023 with about $24 billion in cash and marketable securities, and $18 billion in debt, resulting in a net debt position of $6 billion. - The company continues to execute a disciplined capital allocation approach, including strategic business development, dividends, and share repurchases. - No explicit announcement of new fundraising through debt or equity was made. - The strong credit profile and cash flow generation support future capital needs if any arise.

- Johnson & Johnson is progressively adding manufacturing capacity for Carvykti, including expanding at the original New Jersey launch site, rolling out a manufacturing site in Belgium, and utilizing excess capacity from Novartis. - Outstanding progress has been made in-house scaling the lentivirus component at their factory in Switzerland. - A new facility to support the lentivirus component is under construction in the Netherlands, expected to be available next year. - MedTech is implementing a restructuring program focused on simplifying and focusing operations, including exiting certain markets and product lines to improve future margin profile. - The restructuring program in Orthopedics is a 2-year plan, expected to be completed by end of 2025, with anticipated modest revenue deductions but improved profitability. - Clinical development programs for innovative medicines continue, including the initiation of Anthem phase 2 and ICONIC phase 3 trials for J&J-2113 in autoimmune and psoriasis indications. - Investment in new electrophysiology technologies, including pulse field ablation catheters and cardiac ablation platforms, is advancing.

- MedTech procedural volumes expected to grow 5% to 7% in 2024, maintaining elevated levels vs. historical growth. - MedTech business showing positive evolution with 6.4% pro forma growth year-over-year; growth fueled by procedural increases and new product launches (e.g., PFA catheter in Europe in 2024). - Bariatric business may experience short-term headwinds due to GLP-1 treatments, but surgery and GLP-1 seen as complementary, potentially expanding patient funnel. - Immunology products, especially Tremfya, expected to significantly grow with upcoming ulcerative colitis and Crohn's disease approvals; Tremfya sales grew 25.1% recently. - Pharma business confident in hitting $57 billion revenue target by 2025, driven by key assets (Tremfya, Erleada, Carvykti, Tecvayli) and strong pipeline data expected in 2024-2025. - Oncology pipeline includes promising chemo-free regimens with data presentations at ESMO 2023. - China remains a key growth driver despite VBP headwinds.

- Johnson & Johnson raised 2023 operational sales growth guidance to 8.5%-9% (about $84 billion), with adjusted operational sales growth at 7.2%-7.7% in constant currency. - Adjusted pre-tax operating margin expected to improve by ~50 basis points in 2023 versus prior year, driven by stronger margins. - Adjusted earnings per share (EPS) guidance for 2023 raised to $10.02-$10.08, reflecting 12.5% growth at midpoint and 13.3% reported growth. - Full EPS benefit from 191 million share reduction following Kenvue separation to be reflected in 2024 financials. - 2024 margin guidance not finalized but expected to be similar to 2023 starting levels. - Innovative Medicines pipeline and new product launches (e.g., Tremfya, Carvykti, Tecvayli) expected to drive continued growth. - Stelara biosimilar entry in US not expected in 2024, supporting revenue stability. - Continued strong operational sales growth projected for 2024, with stable procedural volumes in MedTech.

The provided pages from the document do not mention or provide specific information regarding the current or expected orderbook or pending orders for Johnson & Johnson. The discussion primarily focuses on: - Immunology portfolio growth and excitement for upcoming data. - Progress on the Ottava robotic surgery platform. - Strong financial performance and growth guidance. - Updates on key product launches and pipeline developments. - Challenges and strategies related to talc litigation. - Supply chain expansions for therapies like Carvykti. - Market dynamics including pricing and competition. No explicit data or commentary on orderbook size, pending orders, or backlog status is included in the selected pages.